Exo

Santa Clara, CA All United States companies → — Founded 2015

Imaging AI Specialist Medical Device / Hardware Point-of-Care Diagnostics

Cardiology Emergency Medicine Oncology Pulmonology

Cardiology AI Radiology & Imaging AI

Series C — $428M

Claim this company

Products

Lung AI

Exo

Cardiology AI

Exo is pioneering a high-performance, handheld ultrasound platform that uses artificial intelligence for imaging and therapeutic applications. By delivering affordable, easy-to-use medical imaging, Exo empowers healthcare professionals around the world to make critical, real-time decisions that improve patient outcomes.

Contact for pricing

Bladder AI

Exo

Radiology & Imaging AI

Exo Bladder AI is an FDA-cleared, AI-powered software that assists healthcare professionals in accurately and efficiently quantifying bladder volume from ultrasound images, streamlining workflow and report generation.

Not explicitly detailed for bladder ai software; the exo iris handheld ultrasound device, on which it runs, starts at $4,999.

Strain AI

Exo

Cardiology AI

Exo's FDA-cleared Strain AI is an AI-powered medical software that analyzes cardiac ultrasound images to measure Global Longitudinal Strain (GLS), aiding physicians in assessing heart function and detecting conditions like heart failure and cardiotoxicity in adult patients.

Contact for pricing

See all 3 products →

About Exo

Exo is a pioneering medical imaging software and devices company dedicated to transforming healthcare through advanced ultrasound technology and artificial intelligence (AI). The company develops FDA-cleared AI applications for ultrasound diagnosis, provides educational tools, and implements Point-of-Care Ultrasound (POCUS) programs to enhance healthcare delivery.

Their innovative approach integrates advanced nano-materials, novel sensor technologies, sophisticated signal processing, and computation with the scalability of semiconductor manufacturing. This enables the creation of high-performance, handheld ultrasound devices, such as the Exo Iris. These devices offer comprehensive whole-body imaging capabilities, augmented by AI for real-time diagnostic insights across various assessments, including cardiac, lung, and fluid dynamics, as well as specialized applications for bladder, hip, and thyroid conditions.

Exo also provides the Exo Works workflow software, designed to streamline documentation and clinical workflows. The company’s overarching mission is to democratize high-quality medical imaging, making it universally accessible and unconstrained, thereby empowering healthcare professionals to make critical, real-time decisions that ultimately improve patient outcomes.

Focus Areas

Point-of-care ultrasound (POCUS) systems AI-driven ultrasound image interpretation clinical workflow automation for imaging POCUS education and training cardiac assessment lung assessment fluid management population health screening

Business Intelligence

Key Investors	RA Capital Management, Action Potential Venture Capital, Reimagined Ventures, Intel Capital, Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony Innovation Fund, Wanxiang Healthcare Investments, Fiscus Ventures, Ted Koutouzis MD, Solasta Ventures, TDK Ventures, Zach Scheiner, Avidity Partners, BlackRock, Pura Vida Investments, Sands Capital, Samsung Ventures
Partnerships	Samsung Medison, Henry Ford Health, Wellstar MCG Health
Acquisitions	Medo AI (July 2022)
Technology	High-performance handheld ultrasound platform (Exo Iris), AI-based ultrasound image interpretation (SweepAI), cloud-based POCUS workflow and documentation platform (Exo Works), nano-materials, novel sensor technologies, advanced signal processing, semiconductor manufacturing, silicon-based imaging, AI operating system
FDA Clearances	14 cleared products (estimated)

What Physicians Need to Know

Point-of-Care Ultrasound (POCUS) Systems

Exo specializes in the Exo Iris, a high-performance, handheld ultrasound device designed to replace traditional cart-based systems. It features a versatile 3-in-1 probe (phased, curved, linear arrays) for comprehensive scanning needs.

AI-Driven Ultrasound Image Interpretation

Exo offers FDA-cleared AI solutions for real-time image interpretation across various applications, including cardiac (ejection fraction, strain, chamber size, wall thickness), lung (B-lines, effusions, consolidations, atelectasis), bladder volume, and hip dysplasia. Their SweepAIu2122 technology provides guided view capture, instant quality feedback, and automated findings.

Clinical Workflow Automation for Imaging

Exo Worksu2122 is a cloud-based, mobile-first workflow solution that streamlines documentation, quality assurance (QA), and billing for POCUS exams. It allows physicians to manage exams effortlessly in a few taps, integrating with EMR and PACS systems.

POCUS Education and Training

Exo Uu2122 provides AI-powered education and training, acting as a POCUS coach. It includes microlearning videos (TikTok-style), real-time feedback, anatomical labeling, and a progress bar to help clinicians, including novices, rapidly learn and master POCUS.

Cardiac Assessment

The FDA-cleared Cardiac AI Suite on Exo Iris provides automated insights for conditions like heart failure (CHF, HFpEF, HFrEF), hypertrophy, and structural heart changes. It offers automated measurements for ejection fraction (EF), chamber size, strain, and wall thickness for faster, clearer cardiac decisions.

Lung Assessment

Exo's FDA-cleared Lung AI Suite assists in detecting B-lines, effusions, consolidations, and atelectasis in real-time at the bedside. This helps clinicians distinguish edema from effusions and monitor progression for conditions like pneumonia and pulmonary edema.

Fluid Management

Exo's AI tools support fluid management with real-time assessment of IVC collapsibility and bladder volume. This enables rapid bedside insights for conditions like sepsis management and helps guide decisions on fluid administration.

Population Health Screening

Exo offers research-ready diagnostic support for population health screening, including tools for thyroid cancer risk assessment and hip dysplasia screening.

Physician Tip

Exo's integrated ecosystem, comprising the portable Iris device, AI-powered interpretation (SweepAI), streamlined workflow (Exo Works), and comprehensive education (Exo U), is designed to provide immediate answers at the point of care. This significantly reduces the learning curve for POCUS, enhances diagnostic confidence with objective, real-time data, and minimizes administrative burden, allowing you to focus more on patient care. The device's portability and affordability make high-quality ultrasound accessible in diverse clinical settings, from emergency departments to rural clinics.

Exo Works is device-agnostic and offers seamless integration with existing healthcare IT systems, including EMR and PACS, ensuring secure data storage, compliance, and efficient billing. It is Epic App Orchard certified and Cerner CODE program approved, facilitating smooth connectivity within diverse hospital infrastructures. The platform can also function without an internet connection, making it suitable for remote or mobile care settings.

At a glance

Founded 2015

HQ Santa Clara, CA · United States

Team size 192

CEO Sandeep Akkaraju

Funding Series C — $428M

FDA clearances 14 (estimated)

Products 3

Products by Exo

3 products in the directory

Lung AI

Exo

Cardiology AI

Contact for pricing

Bladder AI

Exo

Radiology & Imaging AI

Not explicitly detailed for bladder ai software; the exo iris handheld ultrasound device, on which it runs, starts at $4,999.

Strain AI

Exo

Cardiology AI

Contact for pricing

What the Web Says

Exo (formerly Exos) receives mixed reviews, primarily focusing on its ultrasound technology and as an employer. Product reviews highlight the portability and image quality of their handheld ultrasound devices, particularly for point-of-care applications. Employer reviews often praise the company culture and mission but point to challenges with management and work-life balance.

Overall: Mixed

Strengths

Portable and easy-to-use ultrasound devices (Exo Handheld)
Good image quality for a handheld device
Innovative technology with potential for widespread use
Strong company mission and vision
Positive company culture and smart colleagues (employer reviews)
Opportunities for professional growth

Limitations

Software can be buggy or have connectivity issues
Learning curve for new users of the device
Pricing can be a barrier for some practices
Management issues and lack of clear direction (employer reviews)
Work-life balance challenges and long hours (employer reviews)
Compensation and benefits sometimes cited as below market

Based on reviews from: G2, Glassdoor, Capterra, Reddit, Healthcare IT News/Review Sites

Last updated: 2026-07-18

Videos

News, demos, and interviews about Exo.

Loading videos...

Videos load interactively. If none appear, search YouTube for Exo →

View all on YouTube

Press & Coverage

MarketScreener

European defence companies sign Letter of Intent to establish the Bliksem EXO Consortium: Europe's exo-atmospheric interceptor against medium- and intermediate-range ballistic missiles

Five European defense firms, including Destinus, MBDA, Safran, Airbus, and Thales, have signed a letter of intent to form the Bliksem EXO consortium to develop Europe's first exo-atmospheric interceptor for ballistic missiles. They plan to begin joint engineering work in August 2026 and conduct a test of the kill vehicle in space in 2027.

2026-07

SpaceWatch.GLOBAL

Five European Defense Companies Form Consortium to Develop Sovereign Exo-Atmospheric Missile Interceptor

A consortium of five European defense companies has been established to develop an exo-atmospheric interception capability for medium- and intermediate-range ballistic missiles. The Bliksem EXO Consortium aims to provide Europe with a sovereign defense capability.

2026-07

Science Exploration Press

EXO u2013 Beyond the Cell: A New Journal Led by U.S. National Academy of Medicine Member Professor Brent R. Stockwell

Science Exploration Press launched a new open-access, peer-reviewed journal, EXO u2013 Beyond the Cell, on October 1, 2025. The journal focuses on high-impact research exploring how cells interact with their environments, with Professor Brent R. Stockwell as Editor-in-Chief.

2025-10

Fundz

Exo Imaging $43.9 Million funding round 2025-06-11

Exo Imaging announced a $43.9 million funding round in June 2025, following reports of Samsung's investment in the ultrasound imaging startup. The company's platform aims to reduce imaging costs through advances in nano-materials, sensor technologies, and AI.

2025-06

Exo

Exo hires former U.S. Department of Energy engineer, Michael Miller as Vice President of Technical Services to lead the company through rapid growth and beyond.

Exo, a provider of data and analytics-driven asset inspection and remediation services, hired Michael Miller as Vice President of Technical Services in December 2020 to lead the company through rapid growth.

2020-12

Exo Imaging

Exou00ae Launches FDA-Cleared AI on Exo Irisu2122 to Address Heart Failure

Exo launched new FDA-cleared artificial intelligence tools on its Iris handheld ultrasound system to analyze heart and lung images, particularly beneficial for healthcare providers in underserved settings. The AI assists in detecting and managing heart failure.

2024-04

Exo

Exo Worksu2122 Wins Stevie Award for Healthcare Technology Solution

Exo Works, Exo's point-of-care ultrasound (POCUS) workflow software platform, won a Bronze Stevie Award in the Healthcare Technology Solution category in August 2023. The platform streamlines ultrasound documentation, billing, and quality assurance.

2023-08

Intel Capital

Ultrasound Disruptor Exo Secures $220M in Series C Funding Round

Exo closed a $220 million Series C investment round in August 2021, led by RA Capital Management, to fund the commercialization of its handheld ultrasound device and workflow solution, Exo Works. This brings Exo's total funding to over $320 million.

2021-08

Frequently Asked Questions

What specific POCUS devices and AI solutions does Exo offer, and how do they integrate into existing clinical workflows?

Exo offers the Exo Irisu2122 handheld ultrasound device, which features 3-in-1 imaging capabilities (phased, curved, linear) and is powered by proprietary silicon technology for high-resolution imaging. This device integrates with Exo Worksu2122 software, an AI-powered workflow solution that streamlines image capture, documentation, and billing, and connects with existing PACS, VNA, or EMR systems.

How does Exo's AI technology enhance diagnostic accuracy and efficiency for cardiac, lung, and fluid management assessments?

Exo's AI, including SweepAIu2122, provides real-time guidance, automated measurements, and instant quality feedback for cardiac, lung, and fluid management assessments. Its FDA-cleared AI applications for cardiac (e.g., LVEF, stroke volume) and lung (e.g., B-lines, effusions) help reduce variability, improve diagnostic confidence, and accelerate clinical decision-making at the point of care.

What educational and training resources does Exo provide to ensure effective adoption and proficiency in POCUS for healthcare professionals?

Exo offers Exo Uu2122, an AI-powered scan tutor that provides real-time feedback, anatomical labeling, and microlearning videos to guide users through image acquisition and interpretation. These resources are designed to help clinicians, from novices to experienced users, quickly gain proficiency with Exo's POCUS devices and AI-driven workflows.

What are Exo's data security and compliance measures, particularly concerning HIPAA and other healthcare regulations for patient data?

Exo prioritizes data security and compliance, with its Exo Worksu2122 workflow solution having achieved HITRUST Risk-based, 2-year Certified status and SOC 2 Type II certification. These certifications demonstrate robust controls and adherence to frameworks like HIPAA, ensuring the protection of patient health information (PHI) in their cloud-based platform.

Can Exo's POCUS systems be effectively utilized for population health screening initiatives, and what are the logistical considerations?

The portability and AI-powered simplicity of Exo Iris make it suitable for population health screening initiatives, particularly for conditions like heart failure, lung pathology, and thyroid or hip screening. Logistical considerations would involve scaling training for a broad user base, managing large datasets, and ensuring consistent interpretation across diverse care settings, including rural and underserved communities.

What is the typical pricing structure for Exo's POCUS devices and AI software, and what kind of ongoing support and warranty are included?

The Exo Iris handheld ultrasound device is available starting at $3,500. Exo typically employs a combination of hardware purchase for the Iris and a subscription model for the Exo Works software, which includes AI features and cloud services. Specific details on ongoing support and warranty would be part of these packages, ensuring continued functionality and updates.

What is Exo's strategy for partnerships and long-term company stability, and how does this impact future product development and customer assurance?

Exo has demonstrated strong company stability through significant funding, raising over $320 million from investors like BlackRock, Intel, and Sony. They also engage in strategic partnerships, notably a collaboration and equity investment with Samsung Medison, which aims to accelerate the co-development of advanced ultrasound solutions and ensure long-term innovation and customer assurance.

Related Companies

Suggest an Edit →